Article

Cancer and Metastasis Reviews

, Volume 30, Issue 3, pp 387-395

First online:

Cyclooxygenase-2 and Gastric Cancer

  • Alexandra ThielAffiliated withDepartment of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of HelsinkiGenome-Scale Biology, Research Program Unit, University of Helsinki
  • , Johanna MrenaAffiliated withDepartment of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of HelsinkiDepartment of Gastrointestinal Surgery, Central Hospital of Central Finland
  • , Ari RistimäkiAffiliated withDepartment of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of HelsinkiGenome-Scale Biology, Research Program Unit, University of HelsinkiGenome-Scale Biology, Research Program Unit, Biomedicum Helsinki, University of Helsinki Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Gastric cancer remains a leading cause of cancer-related deaths worldwide, although its incidence has been steadily declining during recent decades. Expression of cyclooxygenase-2 (COX-2) is elevated in gastric carcinomas and in their precursor lesions. COX-2 expression associates with reduced survival in gastric cancer patients, and it has also been shown to be an independent factor of poor prognosis. Several molecular mechanisms are involved in the regulation of COX-2 expression in gastric cancer cell lines, including signal transduction pathways activated by Helicobacter pylori. In gastric tumor models in vivo the role of COX-2 seems to be predominantly to facilitate tumor promotion and growth.

Keywords

Cyclooxygenase-2 Gastric cancer Celecoxib Carcinogenesis Prostaglandin E2